Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milo Gatti

Showing results (71-80 of 168) with videos related to

Pageof 17
Sort By:
Antibiotics (Basel, Switzerland)|September 28, 2023
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative InfectionsPasquale Maria Berrino, Milo Gatti, Matteo Rinaldi, et al.
Antibiotics (Basel, Switzerland)|February 25, 2023
Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug MonitoringRossella Barone, Matteo Conti, Pier Giorgio Cojutti, et al.
International Journal of Antimicrobial Agents|October 6, 2021
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-conceptPier Giorgio Cojutti, Matteo Rinaldi, Milo Gatti, et al.
Expert Opinion on Drug Safety|July 19, 2021
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting systemMilo Gatti, Michele Fusaroli, Emanuel Raschi, et al.
Pharmaceuticals (Basel, Switzerland)|May 28, 2022
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic AppraisalEmanuel Raschi, Michele Fusaroli, Milo Gatti, et al.
British Journal of Clinical Pharmacology|July 9, 2020
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19Milo Gatti, Michele Fusaroli, Paolo Caraceni, et al.
Journal of Nephrology|November 11, 2021
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systemsMilo Gatti, Michele Fusaroli, Emanuel Raschi, et al.
Pharmaceutics|February 25, 2023
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic InfectionsRossella Barone, Matteo Conti, Pier Giorgio Cojutti, et al.
Targeted Oncology|July 30, 2020
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from PharmacovigilanceEmanuel Raschi, Milo Gatti, Francesco Gelsomino, et al.
Pharmaceutics|May 25, 2024
A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic TissueMatteo Conti, Beatrice Giorgi, Rossella Barone, et al.
Pageof 17

Showing results (71-80 of 168) with videos related to

Sort By:
Pageof 17
Antibiotics (Basel, Switzerland)|September 28, 2023
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative InfectionsPasquale Maria Berrino, Milo Gatti, Matteo Rinaldi, et al.
Antibiotics (Basel, Switzerland)|February 25, 2023
Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug MonitoringRossella Barone, Matteo Conti, Pier Giorgio Cojutti, et al.
International Journal of Antimicrobial Agents|October 6, 2021
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-conceptPier Giorgio Cojutti, Matteo Rinaldi, Milo Gatti, et al.
Expert Opinion on Drug Safety|July 19, 2021
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting systemMilo Gatti, Michele Fusaroli, Emanuel Raschi, et al.
Pharmaceuticals (Basel, Switzerland)|May 28, 2022
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic AppraisalEmanuel Raschi, Michele Fusaroli, Milo Gatti, et al.
British Journal of Clinical Pharmacology|July 9, 2020
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19Milo Gatti, Michele Fusaroli, Paolo Caraceni, et al.
Journal of Nephrology|November 11, 2021
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systemsMilo Gatti, Michele Fusaroli, Emanuel Raschi, et al.
Pharmaceutics|February 25, 2023
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic InfectionsRossella Barone, Matteo Conti, Pier Giorgio Cojutti, et al.
Targeted Oncology|July 30, 2020
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from PharmacovigilanceEmanuel Raschi, Milo Gatti, Francesco Gelsomino, et al.
Pharmaceutics|May 25, 2024
A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic TissueMatteo Conti, Beatrice Giorgi, Rossella Barone, et al.
Pageof 17